SARS-CoV-2 virus: Vaccines in development
Qingrui Huang, Jinghua Yan
Abstract
The ongoing COVID-19 pandemic, caused by SARS-CoV-2, is an unprecedented challenge to humanity. Global herd immunity may be necessary before resumption of normal economic and societal activities. Since the beginning of the outbreak, the development of COVID-19 vaccines has proceeded at record speed using nearly all available platforms or strategies to maximize vaccine success. A total of 42 vaccine candidates have now entered clinical trials and encouraging data from several vaccine candidates in phase 1 or 2 clinical trials have been reported. In this review, we examine current COVID-19 vaccine candidates, discuss their strengths and weaknesses, summarize published clinical data and analyze future challenges.
Topics & Concepts
Herd immunityPandemicCoronavirus disease 2019 (COVID-19)Clinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)OutbreakVirologyMedicine2019-20 coronavirus outbreakIntensive care medicineVaccinationDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy